Evolent Health (Evolent Health) Cash And Cash Equivalents : $165 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Evolent Health Cash And Cash Equivalents?

Evolent Health's quarterly cash and cash equivalents increased from Sep. 2023 ($184.54 Mil) to Dec. 2023 ($192.83 Mil) but then stayed the same from Dec. 2023 ($192.83 Mil) to Mar. 2024 ($165.15 Mil).

Evolent Health's annual cash and cash equivalents declined from Dec. 2021 ($266.28 Mil) to Dec. 2022 ($188.20 Mil) but then increased from Dec. 2022 ($188.20 Mil) to Dec. 2023 ($192.83 Mil).

Evolent Health Cash And Cash Equivalents Historical Data

The historical data trend for Evolent Health's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolent Health Cash And Cash Equivalents Chart

Evolent Health Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

101.01

319.00

266.28

188.20

192.83

Evolent Health Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial															157.52	142.53	184.54	192.83	165.15

Evolent Health Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Evolent Health (NYSE:EVH) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Evolent Health Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Evolent Health's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Evolent Health (Evolent Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Evolent Health Inc (NYSE:EVH) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

9EH:Germany

Address

800 N. Glebe Road, Suite 500, Arlington, VA, USA, 22203

Website

https://www.evolenthealth.com

Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. The company's two reportable segments: EHS and Clinical Solutions. The Company's EHS segment provides an integrated administrative and clinical platform for health plan administration and value-based business infrastructure and clinical Solutions segment addresses a broad spectrum of clinical needs, with tailored solutions for specialty care management in oncology and cardiology and increasingly the musculoskeletal markets and holistic total cost of care improvement. It generates a majority of its revenue from Clinical Solutions segment.

Executives

Seth Blackley	officer: President	800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Daniel Joseph Mccarthy	officer: PRESIDENT	800 N GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Emily Ann Rafferty	officer: Chief Operating Officer	800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Toyin Ajayi	director	800 NORTH GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Cheryl Scott	director	800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Mary Bridget Duffy	director	C/O VOCERA COMMUNICATIONS, INC., 525 RACE STREET, SAN JOSE CA 95126
Diane Holder	director	800 GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Richard M Jelinek	director	40 W 47TH STREET, FLOOR 33, NEW YORK NY 10035
Frank J Williams	director, officer: Chief Executive Officer	800 NORTH GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
John Paul Johnson	officer: Chief Financial Officer	800 NORTH GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Jonathan Weinberg	officer: General Counsel	800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Steve Tutewohl	officer: Chief Operating Officer	800 NORTH GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Tunde Sotunde	director	800 N. GLEBE RD, SUITE 500, ARLINGTON VA 22203
Kim Keck	director	30 W. MONROE STREET, SUITE 1200, CHICAGO IL 60603
Craig A. Barbarosh	director	3525 PIEDMONT RD., NE, BUILDING 6, SUITE 700, ATLANTA GA 30305